Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol

Recruiting Observational Study
Coronary Artery Disease
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
1,300 (estimated)
Sponsor
West China Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Percutaneous coronary intervention (PCI) is an important treatment strategy for patients with coronary artery disease. Combined bleeding after PCI significantly increases the risk of death in patients. The search for prognostic predictors and optimal antiplatelet therapy for patients with high bleeding risk (HBR) after PCI has been a hot topic in cardiovascular research. There is no accepted progn…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: PCI patients \>18 years of age and meeting 1 major criterion or 2 minor criteria of the ARC-HBR The ARC-HBR major criteria included: * long-term use of oral anticoagulants; * severe or end-stage chronic kidney disease \[eGFR \<30 ml/(min\*1.73m2 )\]; * hemoglobin \<11 g/dl, spo…
Contacts

No contact information available.